Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pediatric Hematology/Oncology
•
ALL
What is your first choice TKI for pediatric patients with Ph+ ALL who are not on a study?
Answer from: at Academic Institution
The first choice for TKI in children/adolescents with Ph+ ALL should be dasatinib based on a recent study published in JAMA Oncology (Shen et al).
Sign in or Register to read more
7488
Related Questions
What are your top takeaways in Hematologic Malignancies from ASH 2024?
How can the integration of MRD assessments into treatment protocols be optimized to improve risk stratification and therapy decisions in T-ALL?
With the data from AALL1731, how is blinatumomab being implemented for SR and HR leukemia patients not previously planned/randomized to receive blinatumomab?
What is your standard for monitoring triglyceride level during therapy for ALL, particularly in regards to receiving pegaspargase?
When do you consider altering treatment for a patient with metastatic osteosarcoma who showed poor response to upfront therapy with MAP (doxorubicin, cisplatin, methotrexate) chemotherapy?
How quickly do you expect iron stores to decrease after starting iron chelators?
What is your approach to screening a cancer survivor for iron overload, and what is your treatment of choice?
When do you consider testing with stroke gene panels in young stroke patients?
Is there any benefit to using desmopressin over vWF replacement therapy for vWD?
What workup do you consider for a developmentally typical child with multiple large café au lait macules but no other signs of neurofibromatosis?